AR060358A1 - Quinazolinas para la inhibicion de pdk 1 - Google Patents
Quinazolinas para la inhibicion de pdk 1Info
- Publication number
- AR060358A1 AR060358A1 ARP070101448A ARP070101448A AR060358A1 AR 060358 A1 AR060358 A1 AR 060358A1 AR P070101448 A ARP070101448 A AR P070101448A AR P070101448 A ARP070101448 A AR P070101448A AR 060358 A1 AR060358 A1 AR 060358A1
- Authority
- AR
- Argentina
- Prior art keywords
- substituted
- heteroaryl
- aryl
- heterocyclyl
- alkyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/94—Nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
- C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
- C07D451/06—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
- C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
Abstract
Composiciones farmacéuticas que incluyen dichos compuestos y métodos para tratar enfermedades proliferativas tales como cánceres, con los compuestos o composiciones. Reivindicacion 1: Un compuesto de formula 1, en donde: uno de W1 o W2 es R1 y el otro es -L-A1; L es un enlace covalente, carbonilo, carbonilamino, aminocarbonilo, -O-, -S-, -SO-, -SO2-, -NH-, alquilo C1-3, alquilo C1-3 sustituido, o un alquilo interrumpido con -O-, -S-,-SO-, -SO2-, -NH-, carbonilo, carbonilamino, o aminocarbonilo; A1 es arilo, arilo sustituido, heteroarilo, heteroarilo sustituido, heterociclilo, o heterociclilo sustituido; Y es H, alquilo C1-3, halo, ciano, nitro, o amino; R1 se selecciona entre el grupo que consiste de H, alquilo, alquilo sustituido, alquenilo, alquenilo sustituido, alquinilo, alquinilo sustituido, alcoxi, alcoxi sustituido, acilo, acilamino, aciloxi, amino, amino sustituido, aminocarbonilo, aminotiocarbonilo, aminocarbonilamino, aminotiocarbonilamino, aminocarboniloxi, aminosulfonilo, aminosulfoniloxi, aminosulfonilamino, amidino, carboxilo, carboxiléster, (carboxiléster)amino, (carboxiléster)oxi, ciano, halo, hidroxi, nitro, SO3H, sulfonilo, sulfonilo sustituido, sulfoniloxi, tioacilo, tiol, alquiltio, alquiltio sustituido, arilo, arilo sustituido, heteroarilo, heteroarilo sustituido, cicloalquilo, cicloalquilo sustituido, heterociclilo, heterociclilo sustituido, ariloxi, ariloxi sustituido, heteroariloxi, heteroariloxi sustituido, cicloalquiloxi, cicloalquiloxi sustituido, heterocicliloxi, y heterocicliloxi sustituido; R2 y R3 se seleccionan en forma independiente entre el grupo que consiste de H, alquilo, alquilo sustituido, alquenilo, alquenilo sustituido, alquinilo, alquinilo sustituido, alcoxi, alcoxi sustituido, acilo, acilamino, aciloxi, amino, amino sustituido, aminocarbonilo, aminotiocarbonilo, aminocarbonilamino, aminotiocarbonilamino, aminocarboniloxi, aminosulfonilo, aminosulfoniloxi, aminosulfonilamino, amidino, carboxilo, carboxiléster, (carboxiléster)amino, (carboxiléster)oxi, ciano, halo, hidroxi, nitro, SO3H sulfonilo, sulfonilo sustituido, sulfoniloxi, tioacilo, tiol, alquiltio, alquiltio sustituido, arilo, arilo sustituido, heteroarilo, heteroarilo sustituido, cicloalquilo, cicloalquilo sustituido, heterociclilo, y heterociclilo sustituido; y R4 es arilo, arilo sustituido, heteroarilo, heteroarilo sustituido, cicloalquilo, cicloalquilo sustituido, heterociclilo, o heterociclilo sustituido, con la salvedad de que cuando R4 es heteroarilo o heteroarilo sustituido, W2 no es arilo o heteroarilo; o un estereoisomero, tautomero o sal aceptable para uso farmacéutico del mismo.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US79030406P | 2006-04-06 | 2006-04-06 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR060358A1 true AR060358A1 (es) | 2008-06-11 |
Family
ID=38476139
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP070101448A AR060358A1 (es) | 2006-04-06 | 2007-04-04 | Quinazolinas para la inhibicion de pdk 1 |
Country Status (22)
Country | Link |
---|---|
US (1) | US7932262B2 (es) |
EP (1) | EP2004615A2 (es) |
JP (1) | JP2009532486A (es) |
KR (1) | KR20080111114A (es) |
CN (1) | CN101454294A (es) |
AR (1) | AR060358A1 (es) |
AU (1) | AU2007235339A1 (es) |
BR (1) | BRPI0710521A2 (es) |
CA (1) | CA2648529A1 (es) |
CR (1) | CR10427A (es) |
EA (1) | EA200870415A1 (es) |
EC (1) | ECSP088823A (es) |
GT (1) | GT200800202A (es) |
MA (1) | MA30358B1 (es) |
MX (1) | MX2008012852A (es) |
NO (1) | NO20084665L (es) |
PE (1) | PE20080059A1 (es) |
SM (1) | SMP200800059B (es) |
TN (1) | TNSN08375A1 (es) |
TW (1) | TW200808739A (es) |
WO (1) | WO2007117607A2 (es) |
ZA (1) | ZA200808307B (es) |
Families Citing this family (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BRPI0720563A2 (pt) * | 2006-12-22 | 2014-02-04 | Novartis Ag | Quinazolinas para inibição de pdk1 |
UY31137A1 (es) * | 2007-06-14 | 2009-01-05 | Smithkline Beecham Corp | Derivados de quinazolina como inhibidores de la pi3 quinasa |
EP2162444B1 (en) * | 2007-07-11 | 2014-06-04 | Hetero Drugs Limited | An improved process for the preparation of erlotinib hydrochloride |
EP2226315A4 (en) | 2007-12-28 | 2012-01-25 | Carna Biosciences Inc | 2-AMINOQUINAZOLINE DERIVATIVE |
ATE535515T1 (de) * | 2008-01-11 | 2011-12-15 | Hoffmann La Roche | Modulatoren für amyloid beta |
CN102015660A (zh) | 2008-04-23 | 2011-04-13 | 协和发酵麒麟株式会社 | 2-氨基喹唑啉衍生物 |
UA103478C2 (ru) | 2008-05-23 | 2013-10-25 | Новартіс Аг | Производные хинолинов и хиноксалинов как ингибиторы протеинтирозинкиназы |
MX315904B (es) | 2008-05-30 | 2013-11-29 | Amgen Inc | Inhibidores de fosfoinosituro-3 cinasa. |
US20100121052A1 (en) * | 2008-06-20 | 2010-05-13 | Rama Jain | Novel compounds for treating proliferative diseases |
EP2381943A1 (en) * | 2008-12-29 | 2011-11-02 | Fovea Pharmaceuticals | Substituted quinazoline compounds |
KR20130141500A (ko) * | 2010-09-29 | 2013-12-26 | 크리스탈지노믹스(주) | 단백질 키나제 억제 활성을 갖는 신규한 아미노퀴나졸린 화합물 |
WO2013050527A1 (en) | 2011-10-05 | 2013-04-11 | H. Lundbeck A/S | Quinazoline derivatives as pde10a enzyme inhibitors |
KR101360948B1 (ko) * | 2012-01-17 | 2014-02-12 | 한국과학기술연구원 | 신규한 2-아미노퀴나졸린 유도체 및 이를 유효성분으로 포함하는 항암제 |
GB201216017D0 (en) * | 2012-09-07 | 2012-10-24 | Cancer Rec Tech Ltd | Inhibitor compounds |
EP3508204A1 (en) * | 2013-08-23 | 2019-07-10 | Neupharma, Inc. | Certain chemical entities, compositions, and methods |
WO2015083833A1 (ja) * | 2013-12-06 | 2015-06-11 | カルナバイオサイエンス株式会社 | 新規キナゾリン誘導体 |
EP3080085B1 (en) * | 2013-12-09 | 2019-08-14 | UCB Biopharma SPRL | Fused bicyclic heteroaromatic derivatives as modulators of tnf activity |
GB201403536D0 (en) * | 2014-02-28 | 2014-04-16 | Cancer Rec Tech Ltd | Inhibitor compounds |
HUE053654T2 (hu) | 2014-03-26 | 2021-07-28 | Astex Therapeutics Ltd | FGFR- és CMET-inhibitorok kombinációi a rák kezelésére |
KR101879143B1 (ko) | 2014-09-01 | 2018-07-16 | 닛뽕소다 가부시키가이샤 | 2-아미노 치환 벤즈알데히드 화합물을 제조하는 방법 |
SG11201705184PA (en) | 2014-12-24 | 2017-07-28 | Gilead Sciences Inc | Isoquinoline compounds for the treatment of hiv |
BR112017013491A2 (pt) | 2014-12-24 | 2018-01-09 | Gilead Sciences, Inc. | compostos de pirimidina fundida para o tratamento de hiv |
TWI770552B (zh) | 2014-12-24 | 2022-07-11 | 美商基利科學股份有限公司 | 喹唑啉化合物 |
JOP20200201A1 (ar) | 2015-02-10 | 2017-06-16 | Astex Therapeutics Ltd | تركيبات صيدلانية تشتمل على n-(3.5- ثنائي ميثوكسي فينيل)-n'-(1-ميثيل إيثيل)-n-[3-(ميثيل-1h-بيرازول-4-يل) كينوكسالين-6-يل]إيثان-1.2-ثنائي الأمين |
WO2016133935A1 (en) * | 2015-02-17 | 2016-08-25 | Neupharma, Inc. | Certain chemical entities, compositions, and methods |
CN106316965B (zh) * | 2015-07-03 | 2021-08-27 | 上海医药集团股份有限公司 | 喹唑啉类化合物、其中间体、制备方法、药物组合物和应用 |
RU2732576C2 (ru) * | 2015-07-21 | 2020-09-21 | Гуанчжоу Максиновел Фармасьютикалс Ко., Лтд. | Пиримидиновое соединение с конденсированными кольцами, его промежуточное соединение, способ получения, композиция и применение |
RU2736123C1 (ru) | 2015-10-02 | 2020-11-11 | Сентинел Онколоджи Лимитед | Производные 2-аминохиназолина в качестве ингибиторов p70s6 киназы |
CN105753793B (zh) * | 2016-01-19 | 2018-09-04 | 河北医科大学 | 芳甲酰脲偶联喹唑啉类化合物及其制备方法、药物组合物及药物用途 |
JP7101165B2 (ja) | 2016-08-15 | 2022-07-14 | ニューファーマ, インコーポレイテッド | 特定の化学的実体、組成物、および方法 |
GB201705263D0 (en) * | 2017-03-31 | 2017-05-17 | Probiodrug Ag | Novel inhibitors |
GB201709840D0 (en) | 2017-06-20 | 2017-08-02 | Inst Of Cancer Research: Royal Cancer Hospital | Methods and medical uses |
RU2761824C2 (ru) | 2018-08-03 | 2021-12-13 | Закрытое Акционерное Общество "Биокад" | Ингибиторы CDK8/19 |
CN110872243B (zh) * | 2018-08-31 | 2023-03-31 | 四川科伦博泰生物医药股份有限公司 | 磺酰胺类化合物、其制备方法及用途 |
CN109320511A (zh) * | 2018-10-26 | 2019-02-12 | 广安凯特制药有限公司 | 一种高纯度帕博西尼中间体产品及其制备方法 |
CA3139374A1 (en) * | 2019-06-05 | 2020-12-10 | Advanced Technologies For Novel Therapeutics, Llc | Modified peptides and associated methods of use |
US20230192653A1 (en) * | 2020-03-13 | 2023-06-22 | Guangzhou Maxinovel Pharmaceuticals Co., Ltd. | Novel Therapeutic Methods |
US20230406864A1 (en) * | 2020-11-09 | 2023-12-21 | Merck Sharp & Dohme Llc | 7-azole substituted 2-aminoquinazoline inhibitors of hpk1 |
CN117136190A (zh) * | 2021-04-22 | 2023-11-28 | 浙江海正药业股份有限公司 | 芳香稠合环类衍生物及其制备方法和用途 |
CN114533733A (zh) * | 2021-12-31 | 2022-05-27 | 北京鑫开元医药科技有限公司 | 一种异喹啉-1,3-二胺类似物药物制剂及其制备方法 |
CN113999206B (zh) * | 2021-12-31 | 2022-04-12 | 北京鑫开元医药科技有限公司 | 异喹啉-1,3-二胺类似物、制备方法、药物组合物及其应用 |
WO2023138412A1 (en) * | 2022-01-20 | 2023-07-27 | Insilico Medicine Ip Limited | Fused pyrimidin-2-amine compounds as cdk20 inhibitors |
WO2023143135A1 (zh) * | 2022-01-28 | 2023-08-03 | 赛诺哈勃药业(成都)有限公司 | 一种喹唑啉衍生物及其用途 |
CN116672450A (zh) * | 2022-02-23 | 2023-09-01 | 智宠制药(北京)有限公司 | Hpk1抑制剂在治疗干扰素相关疾病中的应用 |
WO2023218241A1 (en) * | 2022-05-13 | 2023-11-16 | Voronoi Inc. | Heteroaryl derivative compounds, and pharmaceutical composition comprising thereof |
US20240092761A1 (en) * | 2022-07-18 | 2024-03-21 | Iambic Therapeutics, Inc. | Quinazoline compounds and methods of use |
Family Cites Families (80)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US73044A (en) | 1868-01-07 | John c | ||
US134846A (en) | 1873-01-14 | Half his eight to william h | ||
US171303A (en) | 1875-12-21 | Improvement in corn-stalk knives | ||
JPS6041077B2 (ja) | 1976-09-06 | 1985-09-13 | 喜徳 喜谷 | 1,2‐ジアミノシクロヘキサン異性体のシス白金(2)錯体 |
US4323581A (en) | 1978-07-31 | 1982-04-06 | Johnson & Johnson | Method of treating carcinogenesis |
IL73534A (en) | 1983-11-18 | 1990-12-23 | Riker Laboratories Inc | 1h-imidazo(4,5-c)quinoline-4-amines,their preparation and pharmaceutical compositions containing certain such compounds |
EP0303697B1 (en) | 1987-03-09 | 1997-10-01 | Kyowa Hakko Kogyo Co., Ltd. | Derivatives of physiologically active substance k-252 |
US4904768A (en) | 1987-08-04 | 1990-02-27 | Bristol-Myers Company | Epipodophyllotoxin glucoside 4'-phosphate derivatives |
JP2766360B2 (ja) | 1988-02-04 | 1998-06-18 | 協和醗酵工業株式会社 | スタウロスポリン誘導体 |
US5238944A (en) | 1988-12-15 | 1993-08-24 | Riker Laboratories, Inc. | Topical formulations and transdermal delivery systems containing 1-isobutyl-1H-imidazo[4,5-c]quinolin-4-amine |
US4929624A (en) | 1989-03-23 | 1990-05-29 | Minnesota Mining And Manufacturing Company | Olefinic 1H-imidazo(4,5-c)quinolin-4-amines |
US5389640A (en) | 1991-03-01 | 1995-02-14 | Minnesota Mining And Manufacturing Company | 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines |
US6410010B1 (en) | 1992-10-13 | 2002-06-25 | Board Of Regents, The University Of Texas System | Recombinant P53 adenovirus compositions |
US5268376A (en) | 1991-09-04 | 1993-12-07 | Minnesota Mining And Manufacturing Company | 1-substituted 1H-imidazo[4,5-c]quinolin-4-amines |
WO1993007153A1 (en) | 1991-10-10 | 1993-04-15 | Schering Corporation | 4'-(n-substituted-n-oxide)staurosporine derivatives |
US5266575A (en) | 1991-11-06 | 1993-11-30 | Minnesota Mining And Manufacturing Company | 2-ethyl 1H-imidazo[4,5-ciquinolin-4-amines |
JPH07505124A (ja) | 1991-11-08 | 1995-06-08 | ザ ユニバーシティ オブ サザン カリフォルニア | ニューロトロフィン活性増強のためのk−252化合物を含む組成物 |
AU661533B2 (en) | 1992-01-20 | 1995-07-27 | Astrazeneca Ab | Quinazoline derivatives |
US5948898A (en) | 1992-03-16 | 1999-09-07 | Isis Pharmaceuticals, Inc. | Methoxyethoxy oligonucleotides for modulation of protein kinase C expression |
IL105325A (en) | 1992-04-16 | 1996-11-14 | Minnesota Mining & Mfg | Immunogen/vaccine adjuvant composition |
US5756494A (en) | 1992-07-24 | 1998-05-26 | Cephalon, Inc. | Protein kinase inhibitors for treatment of neurological disorders |
US5621100A (en) | 1992-07-24 | 1997-04-15 | Cephalon, Inc. | K-252a derivatives for treatment of neurological disorders |
ES2225824T3 (es) | 1992-08-31 | 2005-03-16 | Ludwig Institute For Cancer Research | Nonapeptido aislado derivado del gen mage-3 y presentado por hla-a1, y sus usos. |
WO1994006799A1 (fr) | 1992-09-21 | 1994-03-31 | Kyowa Hakko Kogyo Co., Ltd. | Remede contre la thrombopenie |
ES2173873T5 (es) | 1992-10-28 | 2007-03-01 | Genentech, Inc. | Utilizacion de anticuerpos anti-vegf para el tratamiento del cancer. |
US5395937A (en) | 1993-01-29 | 1995-03-07 | Minnesota Mining And Manufacturing Company | Process for preparing quinoline amines |
CZ288182B6 (en) | 1993-07-15 | 2001-05-16 | Minnesota Mining & Mfg | Imidazo[4,5-c]pyridine-4-amines and pharmaceutical preparations based thereon |
US5352784A (en) | 1993-07-15 | 1994-10-04 | Minnesota Mining And Manufacturing Company | Fused cycloalkylimidazopyridines |
US5478932A (en) | 1993-12-02 | 1995-12-26 | The Board Of Trustees Of The University Of Illinois | Ecteinascidins |
JP3998261B2 (ja) | 1993-12-23 | 2007-10-24 | イーライ・リリー・アンド・カンパニー | プロテインキナーゼc阻害剤 |
US5525613A (en) | 1994-06-16 | 1996-06-11 | Entropin, Inc. | Covalently coupled benzoylecgonine ecgonine and ecgonidine |
US5587459A (en) | 1994-08-19 | 1996-12-24 | Regents Of The University Of Minnesota | Immunoconjugates comprising tyrosine kinase inhibitors |
US6083903A (en) | 1994-10-28 | 2000-07-04 | Leukosite, Inc. | Boronic ester and acid compounds, synthesis and uses |
US5482936A (en) | 1995-01-12 | 1996-01-09 | Minnesota Mining And Manufacturing Company | Imidazo[4,5-C]quinoline amines |
DK0817775T3 (da) | 1995-03-30 | 2001-11-19 | Pfizer | Quinazolinderivater |
GB9508538D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivatives |
US6331555B1 (en) | 1995-06-01 | 2001-12-18 | University Of California | Treatment of platelet derived growth factor related disorders such as cancers |
US5747498A (en) | 1996-05-28 | 1998-05-05 | Pfizer Inc. | Alkynyl and azido-substituted 4-anilinoquinazolines |
US5880141A (en) | 1995-06-07 | 1999-03-09 | Sugen, Inc. | Benzylidene-Z-indoline compounds for the treatment of disease |
WO1997007081A2 (en) | 1995-08-11 | 1997-02-27 | Yale University | Glycosylated indolocarbazole synthesis |
FR2741881B1 (fr) | 1995-12-01 | 1999-07-30 | Centre Nat Rech Scient | Nouveaux derives de purine possedant notamment des prorietes anti-proliferatives et leurs applications biologiques |
CA2231105C (en) | 1995-12-08 | 2005-09-13 | Janssen Pharmaceutica N.V. | Farnesyl protein transferase inhibiting (imidazol-5-yl)methyl-2-quinolinone derivatives |
KR100447918B1 (ko) | 1996-07-25 | 2005-09-28 | 동아제약주식회사 | 대장을포함한위장관보호작용을갖는플라본및플라바논화합물 |
WO1998005769A2 (en) | 1996-08-02 | 1998-02-12 | Genesense Technologies, Inc. | Antitumor antisense sequences directed against r1 and r2 components of ribonucleotide reductase |
CO4950519A1 (es) | 1997-02-13 | 2000-09-01 | Novartis Ag | Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion |
US6126965A (en) | 1997-03-21 | 2000-10-03 | Georgetown University School Of Medicine | Liposomes containing oligonucleotides |
EP1017394B1 (en) | 1997-07-12 | 2005-12-07 | Cancer Research Technology Limited | Cyclin dependent kinase inhibiting purine derivatives |
RS49779B (sr) | 1998-01-12 | 2008-06-05 | Glaxo Group Limited, | Biciklična heteroaromatična jedinjenja kao inhibitori protein tirozin kinaze |
CA2314156C (en) | 1998-05-29 | 2010-05-25 | Sugen, Inc. | Pyrrole substituted 2-indolinone protein kinase inhibitors |
US20030083242A1 (en) | 1998-11-06 | 2003-05-01 | Alphonse Galdes | Methods and compositions for treating or preventing peripheral neuropathies |
CA2727172A1 (en) | 1999-05-26 | 2001-01-04 | Genentech, Inc. | Methods of treatment using anti-erbb antibody-maytansinoid conjugates |
AU6014900A (en) | 1999-07-13 | 2001-01-30 | Kyowa Hakko Kogyo Co. Ltd. | Staurosporin derivatives |
BR0015203A (pt) | 1999-11-05 | 2002-07-16 | Astrazeneca Ab | Derivado de quinazolina, processo para a preparação de um derivado de quinazolina, composição farmacêutica, uso de um composto, e, processo para a produção de um efeito antiangiogênico e/ou redutor de permeabilidade vascular em um animal de sangue quente |
US6982260B1 (en) | 1999-11-22 | 2006-01-03 | Warner-Lambert Company | Quinazolines and their use for inhibiting cyclin-dependent kinase enzymes |
CA2386955A1 (en) | 1999-11-22 | 2001-05-31 | Warner-Lambert Company | Quinazolines and their use for inhibiting cyclin-dependent kinase enzymes |
AR034118A1 (es) | 2000-02-15 | 2004-02-04 | Sugen Inc | Compuestos de 2-indolinonas sustituidas con pirroles inhibidoras de proteinquinasas; sus composiciones farmaceuticas e intermediarios de sintesis |
PT1274718E (pt) | 2000-04-12 | 2007-01-31 | Genaera Corp | Processo para a preparação de esteróis 7. alfa-hidroxi 3- aminosubstítuidos utilizando intermediários com um grupo 7. alfa-hidroxilo desprotegido |
NZ522989A (en) | 2000-06-30 | 2005-06-24 | Glaxo Group Ltd | Quinazoline ditosylate salt compounds |
EP1317442B1 (en) | 2000-09-11 | 2005-11-16 | Chiron Corporation | Quinolinone derivatives as tyrosine kinase inhibitors |
US6677450B2 (en) | 2000-10-06 | 2004-01-13 | Bristol-Myers Squibb Company | Topoisomerase inhibitors |
AU2002245272B2 (en) | 2001-01-16 | 2006-06-29 | Regeneron Pharmaceuticals, Inc. | Isolating cells expressing secreted proteins |
WO2002062826A1 (fr) | 2001-02-07 | 2002-08-15 | Vadim Viktorovich Novikov | Procede de fabrication des peptides |
WO2003004505A1 (en) | 2001-07-02 | 2003-01-16 | Debiopharm S.A. | Oxaliplatin active substance with a very low content of oxalic acid |
KR100484504B1 (ko) | 2001-09-18 | 2005-04-20 | 학교법인 포항공과대학교 | 쿠커비투릴 유도체를 주인 분자로서 포함하고 있는 내포화합물 및 이를 포함한 약제학적 조성물 |
US20030134846A1 (en) * | 2001-10-09 | 2003-07-17 | Schering Corporation | Treatment of trypanosoma brucei with farnesyl protein transferase inhibitors |
TW200306819A (en) | 2002-01-25 | 2003-12-01 | Vertex Pharma | Indazole compounds useful as protein kinase inhibitors |
WO2003077902A1 (en) * | 2002-02-19 | 2003-09-25 | Xenoport, Inc. | Methods for synthesis of prodrugs from 1-acyl-alkyl derivatives and compositions thereof |
MXPA04009541A (es) | 2002-03-29 | 2005-01-25 | Chiron Corp | Benzazoles sustituidos y uso de los mismos como inhibidores de cinasa raf. |
US6900342B2 (en) * | 2002-05-10 | 2005-05-31 | Dabur India Limited | Anticancer taxanes such as paclitaxel, docetaxel and their structural analogs, and a method for the preparation thereof |
US6727272B1 (en) | 2002-07-15 | 2004-04-27 | Unitech Pharmaceuticals, Inc. | Leflunomide analogs for treating rheumatoid arthritis |
US7148342B2 (en) | 2002-07-24 | 2006-12-12 | The Trustees Of The University Of Pennyslvania | Compositions and methods for sirna inhibition of angiogenesis |
US7521062B2 (en) | 2002-12-27 | 2009-04-21 | Novartis Vaccines & Diagnostics, Inc. | Thiosemicarbazones as anti-virals and immunopotentiators |
DE602004021558D1 (de) | 2003-01-17 | 2009-07-30 | Warner Lambert Co | 2-aminopyridin-substituierteheterocyclen als inhibitoren der zellulären proliferation |
WO2004064759A2 (en) | 2003-01-21 | 2004-08-05 | Chiron Corporation | Use of tryptanthrin compounds for immune potentiation |
WO2004087153A2 (en) | 2003-03-28 | 2004-10-14 | Chiron Corporation | Use of organic compounds for immunopotentiation |
WO2005030776A1 (en) | 2003-09-23 | 2005-04-07 | Vertex Pharmaceuticals Incorporated | Pyrazolopyrrole derivatives as protein kinase inhibitors |
CA2580343A1 (en) | 2004-09-14 | 2006-03-23 | Novartis Vaccines And Diagnostics, Inc. | Imidazoquinoline compounds |
JP5079500B2 (ja) * | 2005-04-28 | 2012-11-21 | 協和発酵キリン株式会社 | 2−アミノキナゾリン誘導体 |
WO2006137421A1 (ja) | 2005-06-21 | 2006-12-28 | Kyowa Hakko Kogyo Co., Ltd. | 局所投与剤 |
JO2660B1 (en) | 2006-01-20 | 2012-06-17 | نوفارتيس ايه جي | Pi-3 inhibitors and methods of use |
-
2007
- 2007-04-04 AR ARP070101448A patent/AR060358A1/es unknown
- 2007-04-04 TW TW096112158A patent/TW200808739A/zh unknown
- 2007-04-05 WO PCT/US2007/008592 patent/WO2007117607A2/en active Application Filing
- 2007-04-05 BR BRPI0710521-5A patent/BRPI0710521A2/pt not_active IP Right Cessation
- 2007-04-05 KR KR1020087026508A patent/KR20080111114A/ko not_active Application Discontinuation
- 2007-04-05 EP EP07755008A patent/EP2004615A2/en not_active Withdrawn
- 2007-04-05 MX MX2008012852A patent/MX2008012852A/es not_active Application Discontinuation
- 2007-04-05 EA EA200870415A patent/EA200870415A1/ru unknown
- 2007-04-05 US US12/295,967 patent/US7932262B2/en not_active Expired - Fee Related
- 2007-04-05 AU AU2007235339A patent/AU2007235339A1/en not_active Abandoned
- 2007-04-05 CA CA002648529A patent/CA2648529A1/en not_active Abandoned
- 2007-04-05 JP JP2009504315A patent/JP2009532486A/ja not_active Withdrawn
- 2007-04-05 CN CNA2007800195027A patent/CN101454294A/zh active Pending
- 2007-04-05 SM SM200800059T patent/SMP200800059B/it unknown
- 2007-04-09 PE PE2007000418A patent/PE20080059A1/es not_active Application Discontinuation
-
2008
- 2008-09-25 TN TNP2008000375A patent/TNSN08375A1/en unknown
- 2008-09-29 ZA ZA200808307A patent/ZA200808307B/xx unknown
- 2008-10-01 GT GT200800202A patent/GT200800202A/es unknown
- 2008-10-15 EC EC2008008823A patent/ECSP088823A/es unknown
- 2008-10-27 MA MA31336A patent/MA30358B1/fr unknown
- 2008-11-05 CR CR10427A patent/CR10427A/es not_active Application Discontinuation
- 2008-11-05 NO NO20084665A patent/NO20084665L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
AU2007235339A1 (en) | 2007-10-18 |
GT200800202A (es) | 2009-06-25 |
TW200808739A (en) | 2008-02-16 |
SMAP200800059A (it) | 2008-11-12 |
EA200870415A1 (ru) | 2009-02-27 |
PE20080059A1 (es) | 2008-03-05 |
ZA200808307B (en) | 2010-01-27 |
NO20084665L (no) | 2009-01-06 |
CA2648529A1 (en) | 2007-10-18 |
TNSN08375A1 (en) | 2009-12-29 |
KR20080111114A (ko) | 2008-12-22 |
CN101454294A (zh) | 2009-06-10 |
MA30358B1 (fr) | 2009-04-01 |
US7932262B2 (en) | 2011-04-26 |
CR10427A (es) | 2009-01-27 |
JP2009532486A (ja) | 2009-09-10 |
WO2007117607A9 (en) | 2008-03-06 |
MX2008012852A (es) | 2008-11-28 |
US20100048561A1 (en) | 2010-02-25 |
WO2007117607A2 (en) | 2007-10-18 |
ECSP088823A (es) | 2008-12-30 |
EP2004615A2 (en) | 2008-12-24 |
SMP200800059B (it) | 2009-09-07 |
WO2007117607A3 (en) | 2007-12-21 |
BRPI0710521A2 (pt) | 2012-03-13 |
AU2007235339A8 (en) | 2008-11-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR060358A1 (es) | Quinazolinas para la inhibicion de pdk 1 | |
ES2431163T3 (es) | Inhibidores de PIM quinasa y métodos para su uso | |
AR065231A1 (es) | Quinazolinas inhibidoras de pdk1, composiciones farmaceuticas que las contienen y usos para tratar enfermedades asociadas a proliferacion celular. | |
AR111812A2 (es) | Compuestos y composiciones para el control de nematodos | |
AR096246A1 (es) | Derivados de benzimidazol como inhibidores de bromodominio | |
UY30296A1 (es) | Compuestos fenil amido heterociclicos condensados | |
AR060545A1 (es) | Compuestos de benzoaxol y benzotiazol 6-0- sustituidos y metodos de inhibicion de la senalizacion de csf-1r. composiciones farmaceuticas | |
ES2722409T3 (es) | Moduladores de ROR gamma (RORy) | |
AR079205A1 (es) | Morfolinotiazoles como moduladores alostericos positivos alfa 7 | |
ES2594556T3 (es) | Derivado de naftaleno | |
CO6160266A2 (es) | Derivado de oxopirazina y herbicida | |
AR107293A1 (es) | COMPUESTOS DE PIRIDINA Y PIRIDIMINA COMO INHIBIDORES DE PI3K-g | |
AR062797A1 (es) | Derivados de piperidina como inhibidores de renina, composiciones farmaceuticas. | |
CO6241101A2 (es) | Derivados de quinolina como inhibidores de la p13 quinasa | |
AR067478A1 (es) | Compuestos derivados de morfolina pirimidina | |
ES2653265T3 (es) | Morfinanos sustituidos y el uso de éstos | |
PE20140863A1 (es) | Compuestos de benceno sustituidos con arilo o heteroarilo | |
AR077328A1 (es) | Derivados de oxazina y su uso en el tratamiento de trastornos neurologicos | |
AR047681A1 (es) | Compuestos indazol-carboxamida como agonistas del receptor 5-ht4 | |
PE20221457A1 (es) | Degradadores de moleculas pequenas de helios y procedimientos de uso | |
CO6260076A2 (es) | Derivados de uracilo o timina para el tratamiento de la hepatitis c | |
AR051388A1 (es) | Analogos de 17-hidroxiwortmanina como inhibidores de pi3k | |
AR085615A1 (es) | Derivados de fluoropiridinona utiles como agentes antibacterianos y composiciones farmaceuticas que los contienen | |
AR054482A1 (es) | Derivados de azetidinona para el tratamiento de hiperlipidemias | |
AR083953A1 (es) | Compuestos para tratar enfermedades neurodegenerativas |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |